Showing Results for: “type diabetes”

(NAPS)—Gestational diabetes is something to be concerned about after and not just during pregnancy. Gestational diabetes is diabetes that is found for the first time when a woman is pregnant. If you had gestational diabetes when you were pregnant, you and your child from that pregnancy have a lifelong risk for developing diabetes, a serious disease that can lead to health problems such as heart disease, blindness, kidney disease and amputations. The good news is there are steps you can take to prevent or delay type 2 diabetes and lower that risk for you and your child. Get Tested for Diabetes

Whole Body Digital Twin Technology Enables Personalized Approach to Help Improve Disrupted Metabolism for Individuals with Type 2 Diabetes A new study powered by artificial intelligence (AI), Whole Body Digital Twin, reveals the highest reported rate of remission of type 2 diabetes to date. The findings were presented as a late-breaking poster session at the 82nd Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans, LA. For individuals with type 2 diabetes, remission is defined as sustaining normal blood glucose (blood sugar) levels for at least three months without

For people with type 2 diabetes (T2D) and chronic kidney disease (CKD), canagliflozin, an oral, sodium-glucose co-transporter-2 (SGLT2) inhibitor, has a renal- and cardiovascular-protective effect in reducing the progression of kidney impairment, according to the results of the CREDENCE trial presented today in a symposium at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. In the first of several renal outcomes studies of SGLT2s, the landmark Canagliflozin and Renal Events in Diabetes with Established Nephropathy

In an analysis of the AWARD-7 study, people with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD) who took 1.5 mg of dulaglutide once weekly had a reduction of clinical events associated with end-stage kidney disease (ESKD) including dialysis and with a kidney transplant, and a slower rate of kidney function decline compared to people who used insulin or a lower dose of dulaglutide. The study is an abstract titled “Chronic Kidney Disease (CKD) Outcomes with Dulaglutide (DU) Versus Insulin Glargine (IG) in Type 2 Diabetes (T2D) and Moderate-to-Severe CKD by Albuminuria

The American Heart Association ® and American Diabetes Association’s ® Know Diabetes by Heart™ initiative reveals new ambassador class during American Diabetes Month ® Seven individuals living with type 2 diabetes and representing a wide range of experiences have been selected as the 2020-21 national ambassadors for Know Diabetes by Heart—a joint effort between the American Heart Association and the American Diabetes Association to combat cardiovascular disease, the leading cause of death for people with type 2 diabetes. Compared to people without diabetes, people living with type 2 diabetes

Veterans Health Administration program combining telemonitoring, self-management and medication support improves HbA1c levels within six months In a project entitled “Implementation of Intensive Telehealth Intervention for Rural Patients with Uncontrolled Diabetes,” researchers revealed improved HbA1c levels among rural patients with poorly-controlled type 2 diabetes who participated in a comprehensive telehealth program. The results were presented today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions®. The study found a 1.36% reduction in HBA1c levels after

A new comprehensive Consensus Report to manage type 1 diabetes (T1D) is today being launched by two leading diabetes societies – the European Association for the Study of Diabetes (EASD) and the American Diabetes Association ® (ADA). The final report, launched at the online annual meeting of EASD this week, is also published in Diabetologia (the official journal of EASD) and Diabetes Care (the official journal of ADA). EASD and ADA decided together that a wide-ranging document to capture best practice for T1D was needed after their successful collaboration to provide similar guidance for

To improve gaps in type 2 diabetes care within health care systems and to reduce cardiovascular deaths, heart attacks and strokes for people living with type 2 diabetes, the American Diabetes Association (ADA) and the American Heart Association (AHA) announce the inclusion of their respective, industry-recognized quality improvement programs, Diabetes INSIDE® and Get With The Guidelines®, as part of the Know Diabetes by HeartTM initiative. Additionally, AstraZeneca joins founding sponsors Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance and Novo Nordisk, and national sponsor

Today, the American Diabetes Association ® (ADA) published updates to the Standards of Care in Diabetes—2023 (Standards of Care) on the use of teplizumab in delaying the onset of type 1 diabetes. Type 1 diabetes is a chronic autoimmune disease that affects millions of people worldwide, and its incidence is increasing. Teplizumab is a monoclonal antibody that targets the immune system and has been shown to delay the onset of type 1 diabetes in high-risk individuals. The updated recommendations reflect recent clinical trial results and U.S. Food and Drug Administration (FDA) approval of

The American Diabetes Association (ADA) is raising concerns that a U.S. Department of Agriculture (USDA) school meals proposed rule could weaken nutrition standards and undercut the fight against diabetes. Meals served by the National School Lunch Program and School Breakfast Program today must follow meal patterns that ensure sound, balanced nutrition, based on the Dietary Guidelines for Americans. However, USDA is proposing changes to those meal patterns, requiring lower amounts of red or orange vegetables in school lunches and less fruit when schools operate innovative Breakfast in the